Synergy CHC Corp. (SNYR) AI Stock Analysis

Synergy CHC Corp. provides consumer health care, beauty, and lifestyle products across the United States, Canada, Mexico, and internationally. The company markets brain health nutritional supplements under the FOCUSfactor brand name, alongside lifestyle and wellness products such as tea, shakes, lollipops, supplements, apparel, and exercise accessories under the Flat Tummy brand name. In addition, Synergy CHC offers hand care products under the Hand MD brand, Neuragen homeopathic products, and UrgentRx over-the-counter drugs. Products are distributed through club, mass drug, and other retail channels.

Revenue grew from $40.2M in FY2020 to $42.8M in FY2023, before declining 18.6% to $34.8M in FY2024 and falling 12.8% to $30.4M in FY2025. Gross margin stood at 66.8% in FY2025, down from 75.0% in FY2023, while operating margin shifted from 25.3% in FY2023 to -5.9% in FY2025. Net income dropped from $6.3M in FY2023 and $2.1M in FY2024 to a net loss of -$12.3M in FY2025. For the trailing twelve months ended March 31, 2026, revenue totaled $27.7M with a profit margin of -57.0% and an operating margin of -10.3%. In the quarter ended March 31, 2026, quarterly revenue fell 32.8% year-over-year while quarterly earnings dropped 90.6%.

As of March 31, 2026, Synergy CHC held $292,115 in cash and short-term investments against total debt of $27.7M, resulting in net debt of $27.5M. Total assets stood at $6.5M against negative shareholders' equity of -$25.4M, with a current ratio of 0.93. Free cash flow was negative at -$2.6M in FY2025 following -$4.8M in FY2024. Over the past five years, the company's share count contracted by 87.4%.

Synergy CHC trades at a forward P/E of 0.2x, below the median of 17.3x for its US-listed Healthcare peers. Its enterprise value to EBITDA multiple of 4.4x sits well below the peer median of 12.0x, while its price-to-sales multiple is 0.0x compared to the peer median of 4.1x. The stock closed at $0.01 on September 28, 2026, down 98.1% from its 200-day average. Over the past year, shares fell 99.4%, trailing the S&P 500 return of 16.9%.

One analyst covers Synergy CHC Corp. with a mean price target of $3.75, compared to the last close of $0.01. For the fiscal year ending December 31, 2026, analysts estimate revenue of $31.5M and an EPS of -$0.19, representing an EPS growth estimate of 39.0%. For the next fiscal year, the single analyst forecasts revenue of $36.0M, reflecting 14.4% growth, and EPS of $0.15. The company beat EPS estimates once over the last four quarters.

This page is an AI-written research summary of Synergy CHC Corp. (SNYR). The text was generated on October 30, 2026 from Quotelinks data as of September 28, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SNYR income statement, SNYR balance sheet, SNYR key metrics, SNYR analyst forecast, SNYR chart. See the SNYR stock overview for the latest quote and news.